EP2420219B1 - Entnahmeport - Google Patents

Entnahmeport Download PDF

Info

Publication number
EP2420219B1
EP2420219B1 EP11250656.3A EP11250656A EP2420219B1 EP 2420219 B1 EP2420219 B1 EP 2420219B1 EP 11250656 A EP11250656 A EP 11250656A EP 2420219 B1 EP2420219 B1 EP 2420219B1
Authority
EP
European Patent Office
Prior art keywords
port
administration
administration port
insert member
recess formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11250656.3A
Other languages
English (en)
French (fr)
Other versions
EP2420219A1 (de
Inventor
Gianni Di Stefani
Stephane Spataro
Valèrie Terreur
Giacomino Pardo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to PL11250656T priority Critical patent/PL2420219T3/pl
Priority to SI201130223T priority patent/SI2420219T1/sl
Publication of EP2420219A1 publication Critical patent/EP2420219A1/de
Application granted granted Critical
Publication of EP2420219B1 publication Critical patent/EP2420219B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1406—Septums, pierceable membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1475—Inlet or outlet ports
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/002—Closures to be pierced by an extracting-device for the contents and fixed on the container by separate retaining means

Definitions

  • This invention relates to an administration port for a medical fluid container, a port assembly including such an administration port, and a method of assembling an administration port.
  • Medical fluids such as fluids used for intravenous (IV) therapy, are stored in medical fluid containers.
  • One type of container is a flexible bag formed from multi-layer plastic sheeting.
  • the flexible bags often include a rigid port assembly which has a medication port and an administration port.
  • the medication port allows the addition of medication to fluid within the bag, while the administration port allows removal of fluid from the bag, e.g. during IV therapy.
  • Each of the medication and administration ports includes a seal formation, typically integrally formed within the corresponding port, to isolate the port from the medical fluid until access is desired.
  • a medical operative inserts an IV spike into the administration port.
  • the spike punctures the seal formation to allow fluid to flow from the bag via a fluid conduit within the spike.
  • Some administration ports additionally include a self-sealing membrane which can be penetrated by an IV spike to allow dispensing of fluid, but which seals the administration port on removal of the spike to inhibit unintentional dispensing or leaking of fluid from the bag.
  • administration ports require a user to apply an additional insertion force to an IV spike in order to penetrate the self-sealing membrane.
  • insertion of the IV spike often damages the membrane, thereby degrading its self-sealing performance and leading to unintentional dispensing or leaking of fluid from the associated bag.
  • an administration port for a medical fluid container, comprising a hollow port body receiving an insert member having an engagement portion defined by a cavity and a sealing portion defined by a self-sealing membrane extending across one end of the cavity, the self-sealing membrane including a penetration zone and respective upstream and downstream faces, the administration port being characterised in that the upstream face includes first and second recess formations each of which extends around the penetration zone.
  • first and second recess formations in the upstream face of the self-sealing membrane reduces the volume of material in the corresponding region of the membrane. As a consequence less of the membrane has to be deformed to allow insertion of an IV spike, and so the insertion force a user must apply is reduced.
  • Reducing the required insertion force also reduces the risk of the penetration zone becoming torn or otherwise damaged, and so helps to maintain the sealing integrity of the self-sealing membrane.
  • each recess formation extend around the penetration zone separates each recess formation from the penetration zone, thereby maintaining the configuration of the penetration zone, and so further allowing the membrane to maintain its self-sealing functionality.
  • the provision of discrete engagement and sealing portions allows the insert member to separate the retention and sealing functions, and so accommodate dimensional and structural variations between one IV spike and another without adversely affecting the sealing performance of the sealing portion.
  • At least one recess formation defines an annular recess formation.
  • Such a configuration helps to ensure that the reduction in membrane material is evenly distributed with respect to the inserted IV spike, and so the reduction in IV spike insertion force is also similarly evenly distributed.
  • At least one annular recess formation is centred about the penetration zone. This allows the or each annular recess formation and the penetration zone to work together to facilitate IV spike insertion by helping to provide a uniformly reduced insertion force.
  • the self-sealing membrane includes first and second concentric annular recess formations, the first concentric annular recess formation defining an inner recess formation and the second concentric annular recess formation defining an outer recess formation.
  • Such an arrangement provides a desired reduction in required IV spike insertion force while maintaining self-sealing integrity.
  • the outer recess formation may have a larger cross-sectional shape than the inner recess formation.
  • an outer recess formation having a larger cross-sectional shape than the inner recess formation allows the outer recess formation additionally to act as a hinge. This permits pivoting of membrane material lying inside of the outer recess formation in an upstream direction to further reduce the required IV spike insertion force, and so further facilitate ready IV spike insertion.
  • the penetration zone includes at least one slit formed therein.
  • the provision of one or more slits aids a user in alligning an IV spike with the penetration zone.
  • the cavity defines a cylindrical cavity having a wall extending substantially perpendicular to the self-sealing membrane.
  • a cylindrical cavity having a wall extending substantially perpendicular to the self-sealing membrane enables the whole of the cavity wall to engage with, and hence retain, the body of an IV spike, and so maximise the effectiveness of the engagement portion.
  • the sealing portion lies upstream of the engagement portion.
  • the internal cross-sectional profile of the hollow port body corresponds in shape to the external cross-sectional profile of at least one portion of the insert member.
  • the corresponding external cross-sectional profile of the insert member may extend over the engagement portion and the sealing portion.
  • the external profile of the insert member is larger than the internal profile of the port body. Having an insert member with a larger external profile than the internal profile of the port body generates an interference fit between these elements, and so provides the desired inhibition of relative movement and a fluid-tight seal without the need for extensive secondary processing.
  • the external surface of the insert member is or includes a heat-activated adhesive.
  • a heat-activated adhesive allows for heat-activated mating of the insert member and the port body to prevent relative movement and provide a fluid-tight seal. Heat-activating the mating allows, e.g. for the ready insertion of the insert member into the port body during assembly of the administration port, and ready securing of the insert member within the port body once correctly positioned.
  • the insert member includes an external sheath of heat-activated adhesive.
  • an arrangement provides the external surface of the insert member with an adhesive in a manner that is readily manufacturable in a controllable manner, e.g. by bi-injection moulding.
  • a port assembly for a medical fluid container, comprising a medication port to allow the addition of medication to the medical fluid, the port assembly being characterised by the inclusion of an administration port as described hereinabove.
  • the port assembly shares the advantages of the various:features of the medication port mentioned above.
  • a method of assembling an administration port for a medical fluid container comprising the characterising step of:
  • the method of assembling an administration port further includes the steps of:
  • Heating the administration port to bond the insert member with the port body allows for the ready insertion of the insert member during assembly of the administration port, and ready securing of the insert member within the port body once correctly positioned, e.g. during steam sterilization of the administration port following assembly.
  • An administration port according to a first embodiment of the invention is designated generally by the reference numeral 10.
  • the administration port 10 shown in the figures is part of a rigid port assembly 12 that additionally includes a medication port 14 via which medication can be added to medical fluid held in a bag (not shown) in which the port assembly 12 is located.
  • the administration port 10 is integrally formed with the medication port 14 in a single, unitary port assembly 12. In other embodiments of the invention (not shown) the administration port 10 may be separate from the medication port 14, or the port assembly 12 may omit a medication port 14.
  • the administration port 10 includes a hollow port body 16 that extends lengthwise between an upstream end 18 and a downstream end 20.
  • the downstream end 20 is hermetically sealed by a cap 22 that is removable by rupturing a frangible connection 24 between the downstream end 20 and the cap 22.
  • the administration port 10 also includes a first integrally formed seal formation 26 to isolate the upstream end 18 of the port body 16 from the medical fluid until access is desired.
  • the medication port 14 includes a similar, second integrally formed seal formation 28.
  • the hollow port body 16 receives an insert member 30 that has an engagement portion 32 and a sealing portion 34.
  • the engagement portion 32 is defined by a cavity 36, and the sealing portion 34 is defined by a self-sealing membrane 38 that extends across one end 40 of the cavity 36.
  • sealing portion 34 lies upstream of the engagement portion 32.
  • the self-sealing membrane 38 includes a penetration zone 41 and respective upstream and downstream faces 44, 46.
  • the penetration zone 41 includes a slit 42 formed therein to assist a user in aligning an IV spike 60 with the penetration zone 41.
  • the penetration zone 41 omits a slit and the self-sealing membrane 38 is formed from a material which is sufficiently soft to allow direct insertion of an IV spike 60 there through.
  • the membrane 38 may include a plurality of slits.
  • the upstream face 44 includes first and second concentric annular recess formations 48, 50, each of which is centred about the penetration zone 41 and associated slit 42.
  • Other embodiments of the invention may include one or more recess formations having a different shape and a different configuration relative to one another and to the penetration zone 41.
  • any of the aforementioned recess formations may not extend completely around the penetration zone 41, or may be constituted from a series of discrete recess formation portions which together define the recess formation as a whole.
  • first concentric annular recess formation 48 defines an inner recess formation 52 while the second concentric annular recess formation 50 defines an outer recess formation 54.
  • the inner recess formation 52 has a symmetrical cross-sectional shape which helps to uniformly reduce the insertion force required to insert an IV spike through the membrane 38.
  • the outer recess formation 54 has a larger cross-sectional shape than the inner recess formation 52. Such an arrangement facilitates the hinge functionality of the outer recess formation 54.
  • outer recess formation 54 has an asymmetrical cross-sectional shape, and in particular has a larger inboard volume. This helps to further facilitate the hinge functionality of the outer recess formation 54.
  • the cavity 36 defines a cylindrical cavity 56 which has a wall 58 that extends substantially perpendicular to the membrane 38.
  • the diameter of the cylindrical cavity 36 is approximately 6.0mm.
  • the depth d c of the cavity 36 in the lengthwise direction L is approximately 2.5mm while the depth d m of the self-sealing membrane 38 in the lengthwise direction L is approximately 3.0mm.
  • the internal cross-sectional profile of the port body 16 corresponds in shape to the external cross-sectional profile of the whole of the insert member 30, i.e. the insert member 30 has a uniform external cross-sectional profile, and a uniform cylindrical cross-sectional profile in particular.
  • only one or other of the engagement portion 32 and the sealing portion 34 has an external cross-sectional profile that corresponds in shape to the internal cross-sectional profile of the port body 16.
  • the external profile of the insert member 30 is larger than the internal profile of the port body 16, and in particular the insert member 30 has an external diameter of approximately 8.5mm while the port body 16 has an internal diameter of approximately 8mm. In other embodiments of the invention (not shown) the extent to which the insert member 30 has a larger diameter than the internal diameter of the port body 16 may differ from the aforementioned ratio.
  • the insert member 30 may be formed from a thermo plastic elastomer (TPE) such as DRYFLEX ® which is available from Elasto AB, or THERMOLAST ® that is available from Kraiburg TPE GmbH.
  • TPE thermo plastic elastomer
  • DRYFLEX ® which is available from Elasto AB
  • THERMOLAST ® that is available from Kraiburg TPE GmbH.
  • Such elastomers are sufficiently soft to allow direct penetration of an IV spike 60 through the self-sealing membrane 38.
  • the administration port 10 may be assembled by inserting the insert member 30 into the hollow port body 16 with the interference fit allowing an assembly operative to position the insert member 30 within the port body 16 as desired.
  • the administration port 10 can be heated, e.g. during steam sterilization, to bond the insert member 30 within the port body 16.
  • a medical operative removes, e.g. snaps off, the cap 22 from the administrative port 10 to allow access to the port body 16.
  • the operative then inserts an IV spike 60 into the port body 16 via the downstream end 20 thereof, as shown in Figure 2 .
  • the slit 42 in the self-sealing membrane 38 aids the operative in aligning the body 62 of the IV spike 60 with the penetration zone 41.
  • the inner recess formation 52 reduces the extent to which the membrane 38 must deform to accommodate the IV spike 60 and so reduces the insertion force required.
  • the outer recess formation 54 provides a further reduction in the required deformation of the membrane 38 to accommodate the IV spike 60.
  • the outer recess formation 54 also acts like a hinge to allow pivoting of the membrane material lying inside of the outer recess formation 54 into the port body 16.
  • the outer recess formation 54 provides a further reduction in the insertion force required to insert the IV spike 60 into the administration port 10.
  • the reductions in required insertion force provided by the inner and outer recess formations 52, 54 reduces the risk of the slit 42 becoming torn or the membrane 38 becoming damaged.
  • the spike body 62 lies within the cylindrical cavity 56 of the engagement portion 32.
  • the wall 58 of the cylindrical cavity 56 deforms to accommodate any dimensional or structural deviation of the spike body 62 while maintaining a gripping engagement with the spike body 62.
  • the engagement portion 32 retains the spike body 62 and forms a fluid-tight seal between the port body 16 and the spike body 62.
  • the operative overcomes the gripping engagement provided by the engagement portion 32 to withdraw the spike body 62 from within the insert member 30.
  • the self-sealing membrane 38 adopts its original, pre-penetration, configuration (as shown in Figure 2 ) to create a fluid-tight seal within the port body 16 and so inhibit leaking or further discharge of fluid from the bag.
  • the insert member 30 may include an external sheath (not shown) of heat-activated adhesive.
  • a modified insert member may be formed from a TPE such as thermoplastic silicone vulcanizate (TPSiV) while the external sheath may be formed from a hot melt adhesive such as ethylene vinyl acetate (EVA).
  • TPE thermoplastic silicone vulcanizate
  • EVA hot melt adhesive
  • Such an insert member and the external sheath may be formed by bi-injection molding these two constituent materials.
  • An administration port 10 including the modified insert member may be assembled in the same manner as set out above in connection with the insert member 30. Heating the administration port 10 activates the adhesive to bond the modified insert member within the port body 16.
  • Such an administration port 10 also functions in the same manner as described above in connection with the first insert member 30.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (16)

  1. Verabreichungsport (10) für einen Behälter mit medizinischer Flüssigkeit, umfassend einen hohlen Portkörper (16), der ein Einsatzglied (30) aufnimmt bzw. empfängt, das einen Eingriffsabschnitt (32), der durch einen Hohlraum (36) definiert ist, und einen Dichtungsabschnitt (34) aufweist, der durch eine selbstdichtende Membran (38) definiert ist, die sich über ein Ende des Hohlraums (36) erstreckt, wobei die selbstdichtende Membran (38) eine Penetrationszone (41) und jeweilige stromaufwärtige und stromabwärtige Flächen (44, 46) enthält, wobei der Verabreichungsport (10) dadurch gekennzeichnet, dass die stromaufwärtige Fläche (44) erste und zweite Aussparungs- bzw. Vertiefungsformationen (48, 50) enthält, von denen sich jede um die Penetrationszone (41) herum erstreckt.
  2. Verabreichungsport (10) nach Anspruch 1, wobei zumindest eine Aussparungsformation (48, 50) eine ringförmige Aussparungsformation (48, 50) definiert.
  3. Verabreichungsport (10) nach Anspruch 1 oder Anspruch 2, wobei zumindest eine ringförmige Aussparungsformation (48, 50) um die Penetrationszone (41) herum zentriert ist.
  4. Verabreichungsport (10) nach einem der vorhergehenden Ansprüche, enthaltend eine selbstdichtende Membran (38), die erste und zweite konzentrische ringförmige Aussparungs- bzw. Vertiefungsformationen (48, 50) aufweist, wobei die erste konzentrische ringförmige Aussparungsformation (48) eine innere Aussparungs- bzw. Vertiefungsformation (52) definiert und die zweite konzentrische ringförmige Aussparungsformation (50) eine äußere Aussparungs- bzw. Vertiefungsformation (54) definiert.
  5. Verabreichungsport (10) nach Anspruch 4, wobei die äußere Aussparungsformation (54) eine größere Querschnittsform als die innere Aussparungsformation (52) aufweist.
  6. Verabreichungsport (10) nach einem der vorhergehenden Ansprüche, wobei die Penetrationszone (41) zumindest einen Schlitz (42) enthält, der in dieser gebildet ist.
  7. Verabreichungsport (10) nach einem der vorhergehenden Ansprüche, wobei der Hohlraum (36) einen zylindrischen Hohlraum (56) mit einer Wand (58) definiert, die sich im Wesentlichen senkrecht zu der selbstdichtenden Membran (38) erstreckt.
  8. Verabreichungsport (10) nach einem der vorhergehenden Ansprüche, wobei der Dichtungsabschnitt (34) stromaufwärts des Eingriffsabschnitts (32) liegt.
  9. Verabreichungsport (10) nach einem der vorhergehenden Ansprüche, wobei das Innenquerschnittsprofil des hohlen Portkörpers (16) in seiner Form dem Außenquerschnittsprofil zumindest eines Abschnitts des Einsatzglieds (30) entspricht.
  10. Verabreichungsport (10) nach Anspruch 9, wobei sich das entsprechende Außenquerschnittsprofil des Einsatzglieds (30) über den Eingriffsabschnitt (32) und den Dichtungsabschnitt (34) erstreckt.
  11. Verabreichungsport (10) nach Anspruch 9 oder Anspruch 10, wobei das Außenprofil des Einsatzglieds (30) größer ist als das Innenprofil des Portkörpers (16).
  12. Verabreichungsport (10) nach Anspruch 9 oder Anspruch 10, wobei die Außenfläche bzw. -oberfläche des Einsatzglieds (30) ein wärmeaktivierbarer Klebstoff ist oder diesen enthält.
  13. Verabreichungsport (10) nach Anspruch 12, wobei das Einsatzglied (30) einen Außenmantel bzw. -hülle aus wärmeaktivierbarem Klebstoff enthält.
  14. Portanordnung (12) für einen Behälter mit medizinischer Flüssigkeit, umfassend einen Medikationsport (14), der die Zugabe von Medikament zu der medizinischen Flüssigkeit erlaubt, wobei die Portanordnung durch das Enthalten eines Verabreichungsports (10) nach einem der Ansprüche 1 bis 13 gekennzeichnet ist.
  15. Verfahren zum Montieren bzw. Zusammenbauen eines Verabreichungsports (10) für einen Behälter mit medizinischer Flüssigkeit, wobei der Verabreichungsport (10) einen hohlen Portkörper (16) enthält, wobei das Verfahren den kennzeichnenden Schritt umfasst:
    Einsetzen, in den hohlen Portkörper (16), eines Einsatzglieds (30), das einen Eingriffsabschnitt (32), der durch einen Hohlraum (36) definiert ist, und einen Dichtungsabschnitt (34) aufweist, der durch eine selbstdichtende Membran (38) definiert ist, die sich über ein Ende des Hohlraums (36) erstreckt, wobei die selbstdichtende Membran (38) eine Penetrationszone (41) und jeweilige stromaufwärtige und stromabwärtige Flächen (44, 46) enthält, wobei die stromaufwärtige Fläche (44) erste und zweite Aussparungs- bzw. Vertiefungsformationen (48, 50) enthält, von denen sich jede um die Penetrationszone (41) herum erstreckt.
  16. Verfahren zum Montieren eines Verabreichungsports (10) nach Anspruch 15, ferner enthaltend die Schritte:
    Heißsiegeln eines stromabwärtigen Endes des Portkörpers (16), um den Portkörper (16) hermetisch abzudichten; und
    Erwärmen des Verabreichungsports (10), um das Einsatzglied (30) mit dem Portkörper (16) zu verbinden.
EP11250656.3A 2010-08-19 2011-07-12 Entnahmeport Active EP2420219B1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL11250656T PL2420219T3 (pl) 2010-08-19 2011-07-12 Przyłącze do podawania
SI201130223T SI2420219T1 (sl) 2010-08-19 2011-07-12 Priključek za odjem

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1013899.8A GB2483055A (en) 2010-08-19 2010-08-19 Administration port for medical fluid containers

Publications (2)

Publication Number Publication Date
EP2420219A1 EP2420219A1 (de) 2012-02-22
EP2420219B1 true EP2420219B1 (de) 2014-06-04

Family

ID=42984362

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11250656.3A Active EP2420219B1 (de) 2010-08-19 2011-07-12 Entnahmeport

Country Status (8)

Country Link
EP (1) EP2420219B1 (de)
DK (1) DK2420219T3 (de)
ES (1) ES2498240T3 (de)
GB (1) GB2483055A (de)
HR (1) HRP20140630T1 (de)
PL (1) PL2420219T3 (de)
RS (1) RS53393B (de)
SI (1) SI2420219T1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250017821A1 (en) * 2023-07-14 2025-01-16 Entegris, Inc. Bag fitment having internal spike port

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030128125A1 (en) 2002-01-04 2003-07-10 Burbank Jeffrey H. Method and apparatus for machine error detection by combining multiple sensor inputs
US9717840B2 (en) 2002-01-04 2017-08-01 Nxstage Medical, Inc. Method and apparatus for machine error detection by combining multiple sensor inputs
EP2759284A1 (de) * 2013-01-28 2014-07-30 B. Braun Melsungen AG Überziehkappe für einen pharmazeutischen Behälter
ES2939140T3 (es) * 2013-08-08 2023-04-19 Illumina Inc Sistema de fluido para el suministro de reactivos a una celda de flujo
FR3087342B1 (fr) * 2018-10-17 2020-11-13 Stemcis Bocal et dispositif de recuperation et de preparation de tissus adipeux

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3136440A (en) * 1963-06-25 1964-06-09 Becton Dickinson Co Self sealing pierceable stopper for sealed containers
US5895383A (en) * 1996-11-08 1999-04-20 Bracco Diagnostics Inc. Medicament container closure with recessed integral spike access means
US6179823B1 (en) * 1998-01-20 2001-01-30 Bracco Research Usa Multiple use universal connector flexible medical container assembly
DE102004051300C5 (de) * 2004-10-20 2013-01-24 Fresenius Kabi Deutschland Gmbh Verschlusskappe für mit medizinischen Flüssigkeiten befüllte Behältnisse
US20060276769A1 (en) * 2004-12-23 2006-12-07 John Domkowski Medical fluid container
DE102007005407A1 (de) * 2007-02-03 2008-08-07 Fresenius Kabi Deutschland Gmbh Verschlusskappe für ein Behältnis zur Aufnahme von medizinischen Flüssigkeiten und Behältnis zur Aufnahme von medizinischen Flüssigkeiten

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250017821A1 (en) * 2023-07-14 2025-01-16 Entegris, Inc. Bag fitment having internal spike port

Also Published As

Publication number Publication date
SI2420219T1 (sl) 2014-08-29
RS53393B (sr) 2014-10-31
DK2420219T3 (da) 2014-08-11
EP2420219A1 (de) 2012-02-22
ES2498240T3 (es) 2014-09-24
GB201013899D0 (en) 2010-10-06
HRP20140630T1 (hr) 2014-09-26
GB2483055A (en) 2012-02-29
PL2420219T3 (pl) 2014-11-28

Similar Documents

Publication Publication Date Title
EP2420219B1 (de) Entnahmeport
US11266784B2 (en) Disinfecting cap for medical connectors
US8622972B2 (en) Peripheral catheter assembly and method of using it
EP3479868B1 (de) Zusammenklappbares ventil
EP2376147B1 (de) Verbesserter arzneibehälter
EP3756723B1 (de) Rückflussfreies ventil mit innengewinde mit geringem primingvolumen
EP3383478B1 (de) Flexible kappe für konische verbinder
EP3199200B1 (de) Medizinischer verbinder
US11266779B2 (en) IV set spike with enhanced removal force
US12440659B2 (en) Dual ended disinfecting cap for stopcock valves
EP2074982A1 (de) Kommunikationselement und medizinischer behälter damit
JP3594604B2 (ja) 流体ポートの再封止部材
CN105188815B (zh) 用于流体路径的无菌度增强的封闭
EP4000679B1 (de) Verbindungsstück für einen beutel, der flüssige lösungen für medizinische oder ernährungszwecke enthält
US20240216223A1 (en) Cap for a fluid container, fluid container comprising such cap and method for manufacturing such cap
JP3231085U7 (de)
JP6345391B2 (ja) 雄コネクタ
US20190117510A1 (en) Port, dispensing system comprising such a port, and manufacturing method
JP5125051B2 (ja) 医療用接続具
JP2014136074A (ja) コネクタ用弁体及びコネクタ

Legal Events

Date Code Title Description
AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120821

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131219

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 670609

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140615

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20140630

Country of ref document: HR

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011007406

Country of ref document: DE

Effective date: 20140717

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20140808

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20140604

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2498240

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140924

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20140630

Country of ref document: HR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20140401396

Country of ref document: GR

Effective date: 20140901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140604

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140604

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140604

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 17291

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141006

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141004

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011007406

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140604

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150305

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E022572

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011007406

Country of ref document: DE

Effective date: 20150305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140604

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140712

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20170621

Year of fee payment: 7

Ref country code: RO

Payment date: 20170622

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20170728

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20170622

Year of fee payment: 7

Ref country code: HU

Payment date: 20170626

Year of fee payment: 7

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140604

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 17291

Country of ref document: SK

Effective date: 20180712

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180713

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20190305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180713

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190207

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180712

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140630

Country of ref document: HR

Payment date: 20190711

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180712

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140630

Country of ref document: HR

Payment date: 20200617

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140630

Country of ref document: HR

Payment date: 20210505

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140630

Country of ref document: HR

Payment date: 20220519

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220524

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140630

Country of ref document: HR

Payment date: 20230515

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140630

Country of ref document: HR

Payment date: 20240703

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20250620

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250624

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250619

Year of fee payment: 15

Ref country code: DK

Payment date: 20250619

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20250630

Year of fee payment: 15

Ref country code: NO

Payment date: 20250623

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250620

Year of fee payment: 15

Ref country code: BE

Payment date: 20250619

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250620

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20250627

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250623

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20250619

Year of fee payment: 15

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140630

Country of ref document: HR

Payment date: 20250702

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250801

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250620

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20250619

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HR

Payment date: 20250702

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20250623

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250801

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20250630

Year of fee payment: 15